PROK Earnings

PROK reported its earnings on 2025-05-09, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.16 by 0% . The stock experienced a 3.06% price change on the earnings day and a 10.16% change over the next five days, reflecting market reactions to the results.

Following PROK's earnings announcement on 2025-05-09, the stock price moved by 3.06% on the day of the release. Over the subsequent five days, it saw a 10.16% change. Historically, PROK's stock price tends to shift by an average of +4.65% in the 10 days leading up to earnings and -0.61% in the 10 days following, providing insight into potential market.

For 2025/Q3, analysts estimate PROK’s annual revenue to reach 44.25K, while the EPS is projected at -0.15. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 10.41% and EPS estimates Revise Downward by -91.19% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between PROK's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 10.41%, while EPS estimates moved Revise Downward by -91.19% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PROK's stock price typically moves by +4.65% in the 10 days before its earnings and -0.61% in the 10 days after. For the upcoming 2025/Q3 earnings, analysts expect an EPS of -0.15 and revenue of 44.25K.

The earnings call highlights promising Phase II study results for REACT, showing potential in preserving kidney function in high-risk CKD patients. The Q&A reveals strategic focus on stage 4 CKD patients and addressing evolving treatment landscapes, which align with medical and payer feedback. Despite some delays and uncertainties, the company's proactive approach in modifying studies to enhance success potential reflects positively. No significant negative factors were discussed, leading to a positive sentiment overall.